Literature DB >> 15589171

GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

Tim D Eubank1, Ryan Roberts, Michelle Galloway, Yijie Wang, David E Cohn, Clay B Marsh.   

Abstract

GM-CSF promotes homeostasis of myeloid cells. We report that GM-CSF upregulates mRNA and protein production of the soluble form of membrane bound VEGF receptor-1 (sVEGFR-1) in human monocytes. This sVEGFR-1 was biologically active, as cell-free supernatants from GM-CSF-stimulated monocytes blocked detection of endogenously expressed VEGF and inhibited endothelial cell migration and tube formation, even in the presence of exogenous rhVEGF. VEGF activity was recovered by neutralizing sVEGFR-1. To determine whether these events were important in vivo, Matrigel plugs were incubated with rhVEGF, rhGM-CSF, or rhGM-CSF/rhVEGF and injected into mice. Plugs containing GM-CSF or GM-CSF/VEGF had less endothelial cell invasion than plugs containing rhVEGF and were similar to plugs incubated with PBS alone. Neutralizing antibodies specific for sVEGFR-1 injected in these plugs reversed the effects of GM-CSF or GM-CSF/VEGF, while an isogenic antibody did not. Thus, GM-CSF and monocytes play a vital role in angiogenesis through the regulation of VEGF and sVEGFR-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589171      PMCID: PMC6893854          DOI: 10.1016/j.immuni.2004.10.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  28 in total

Review 1.  VPF/VEGF and the angiogenic response.

Authors:  H F Dvorak
Journal:  Semin Perinatol       Date:  2000-02       Impact factor: 3.300

2.  Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.

Authors:  Y Cao; M S O'Reilly; B Marshall; E Flynn; R W Ji; J Folkman
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 3.  VEGF receptor signaling and endothelial function.

Authors:  S Kliche; J Waltenberger
Journal:  IUBMB Life       Date:  2001-07       Impact factor: 3.885

4.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

Authors:  R L Kendall; G Wang; K A Thomas
Journal:  Biochem Biophys Res Commun       Date:  1996-09-13       Impact factor: 3.575

5.  Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor.

Authors:  K Uchida; S Uchida; K Nitta; W Yumura; F Marumo; H Nihei
Journal:  Am J Physiol       Date:  1994-01

6.  Inhibition of vascularization in tumor growth.

Authors:  M Scalerandi; B Capogrosso Sansone
Journal:  Phys Rev Lett       Date:  2002-11-01       Impact factor: 9.161

Review 7.  Vascular endothelial growth factor (VEGF) and its receptors.

Authors:  G Neufeld; T Cohen; S Gengrinovitch; Z Poltorak
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

8.  M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes.

Authors:  Tim D Eubank; Michelle Galloway; Christine M Montague; W James Waldman; Clay B Marsh
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

9.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.

Authors:  N Ferrara; K Carver-Moore; H Chen; M Dowd; L Lu; K S O'Shea; L Powell-Braxton; K J Hillan; M W Moore
Journal:  Nature       Date:  1996-04-04       Impact factor: 49.962

10.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  43 in total

1.  Modulation of cytokine and chemokine secretions in rhesus monkey trophoblast co-culture with decidual but not peripheral blood monocyte-derived macrophages.

Authors:  Ann E Rozner; Svetlana V Dambaeva; Jessica G Drenzek; Maureen Durning; Thaddeus G Golos
Journal:  Am J Reprod Immunol       Date:  2011-01-31       Impact factor: 3.886

2.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

Review 3.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 4.  Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Michael J Ryan; Jeffrey S Gilbert; Sydney R Murphy; Joey P Granger
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

5.  VEGF induces neuroglial differentiation in bone marrow-derived stem cells and promotes microglia conversion following mobilization with GM-CSF.

Authors:  Bat-Chen R Avraham-Lubin; Nitza Goldenberg-Cohen; Tamilla Sadikov; Nadir Askenasy
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

6.  Temporal phenotypic features distinguish polarized macrophages in vitro.

Authors:  David W Melton; Linda M McManus; Jonathan A L Gelfond; Paula K Shireman
Journal:  Autoimmunity       Date:  2015-03-31       Impact factor: 2.815

7.  Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.

Authors:  Julie M Roda; Laura A Sumner; Randall Evans; Gary S Phillips; Clay B Marsh; Timothy D Eubank
Journal:  J Immunol       Date:  2011-07-15       Impact factor: 5.422

8.  Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Authors:  T Hoeres; M Wilhelm; M Smetak; E Holzmann; G Schulze-Tanzil; J Birkmann
Journal:  Clin Exp Immunol       Date:  2018-01-04       Impact factor: 4.330

9.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

Authors:  Saul J Priceman; James L Sung; Zory Shaposhnik; Jeremy B Burton; Antoni X Torres-Collado; Diana L Moughon; Mai Johnson; Aldons J Lusis; Donald A Cohen; M Luisa Iruela-Arispe; Lily Wu
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

10.  Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model.

Authors:  Duan Chen; Julie M Roda; Clay B Marsh; Timothy D Eubank; Avner Friedman
Journal:  Bull Math Biol       Date:  2012-10-17       Impact factor: 1.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.